Total Funding
51
64
Total FundingPost-IPO Debt raised
Growth Score
-12 pts
Heat Score
18 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
37556
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.
- Bing C Wang: Chief Financial OfficerPast Role: Barclays Investment Bank, Director
Jon Voss: EVP Global Quality, CellectisPast Role: Avedro, VP Quality
About the Company
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers.
Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic
malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.
